🟢 MetaVia is trading 5.46% up in pre-market with no clear catalyst identified

MetaVia is trading 5.46% up at $1.79 in pre-market, with no clear company-specific catalyst identified for September 9, 2026.

• The latest company update was its August 6 second-quarter results and corporate update; prior clinical-trial progress dates to July 9.
• Futures are mixed, with the S&P 500 up 0.04% and Nasdaq Composite up 0.09%.
• The gain remains an unclear, likely stock-specific trading move.